DI-fusion, le Dépôt institutionnel numérique de lULB, est loutil de référencementde la production scientifique de lULB.Linterface de recherche DI-fusion permet de consulter les publications des chercheurs de lULB et les thèses qui y ont été défendues.
Review question Does molecular-targeted therapy (a type of treatment specifically targeting cancer cells) benefit people with late-stage stomach cancer?. Background Due to the lack of clinical symptoms, many stomach cancers are diagnosed at a very late stage (stage III or stage IV), for which surgery cannot be the best option anymore. The effects of chemotherapy and radiotherapy on late-stage stomach cancer are very limited, leading to a low possibility of survival for people with the disease (fewer than one in five people survive for longer than five years). Recent research suggested that molecular-targeted therapy may prolong the survival time for people with late-stage stomach cancer. However, the therapeutic benefit of this treatment is still under debate.. Study characteristics We searched databases until December 2015 for randomized controlled trials (clinical trials where people are randomly allocated to one of two or more treatment groups) in adults (aged 18 years or over), diagnosed ...
Cancer Therapy Advisor provides obsteticians and gynecologists with the latest information to correctly diagnose obgyn conditions, recommend procedures and guides. Visit often for updates and new information.
Molecular-targeted agents are increasingly used for the treatment of cancer. However, the attrition rate for drugs that enter early clinical trials is higher than for other branches of internal medicine, suggesting that preclinical development has not been successful in identifying agents that can modify the outcome of human cancer. New preclinical strategies including genetically engineered mouse models and small-interfering RNAs are being used to evaluate novel agents, and have aided in the development of compounds, such as inhibitors of phosphatidylinositol 3-kinase or poly(ADP-ribose) polymerase. In addition, these techniques have helped in the identification of promising combinations of targeted drugs. In this Review, we describe methods for the preclinical evaluation of novel agents, their limitations, and strategies for improvement. © 2011 Macmillan Publishers Limited. All rights reserved ...
Advanced Cancer Therapeutics (ACT) is is focused on the discovery and early development of novel cancer therapeutics as well as selection for partnership,
Our laboratory works at the interface of engineering and medicine, ​with a motivation on making stem cell and molecular therapies and effective method to model and treat diseases.
Our laboratory works at the interface of engineering and medicine, ​with a motivation on making stem cell and molecular therapies and effective method to model and treat diseases.
Orellana-Gavaldà, J. M., Herrero, L., Malandrino, M. I., Pañeda, A., Sol Rodríguez-Peña, M., Petry, H., Asins, G., Van Deventer, S., Hegardt, F. G. and Serra, D. (2011), Molecular therapy for obesity and diabetes based on a long-term increase in hepatic fatty-acid oxidation . Hepatology, 53: 821-832. doi: 10.1002/hep.24140 ...
Technology Networks is an internationally recognised publisher that provides access to the latest scientific news, products, research, videos and posters.
Promedior is a clinical-stage biotechnology company pioneering the development of targeted therapeutics to treat diseases involving fibrosis.
Video-reportage of the presentation given by Prof. Piergiuseppe Pelicci on the development of the new molecular anti cancer drugs.
UT Southwestern Medical Center researchers have discovered a new therapeutic target for incurable, rare type of soft-tissue cancer.
Health, ...A new therapeutic target for lung cancer has been discovered by resear...Lung cancer is one of the worlds most common cancers and a leading ca...New innovative therapies are important not only because of the high mo......,New,therapeutic,target,for,lung,cancer,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
la Haba-Rodriguez JR De, Minckwitz G von, M Martín, S Morales, C Crespo, A Guerrero, A Anton-Torres, M Gil, M Muñoz, E Carrasco, C Rodríguez-Martin, I Porras, B Aktas, W Schoenegg, J Tio, K Mehta, S Loibl, Behalf of GEICAM and GBG On ...
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Th
Clarke, M., Mackay, A., Ismer, B., Pickles, J.C., Tatevossian, R.G., & Newman, S. (2020). Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discovery, 10(7), 942-963. doi:10.1158/2159-8290.CD-19- ...
Text of H.R. 1730: Cancer Drug Parity Act of 2019 as of Mar 13, 2019 (Introduced version). H.R. 1730: Cancer Drug Parity Act of 2019
As per the recent study conducted by Reports and Data, the Global Hematological Cancers Therapeutics Market was valued at USD 34.38 Billion in 2019 and is
Scarring, arising as a natural reaction to surgery performed to improve an underlying ophthalmic problem such as glaucoma, can cause significant impairment of vision. Our site has one of the strongest track records in the world in the fields of preventing ocular scarring, promoting cell regeneration and developing novel medicines. The overarching aim of this research theme is to accelerate the availability and range of innovative cellular and molecular therapies which meet many unmet needs in ophthalmology and in the human body. ...
Scarring, arising as a natural reaction to surgery performed to improve an underlying ophthalmic problem such as glaucoma, can cause significant impairment of vision. Our site has one of the strongest track records in the world in the fields of preventing ocular scarring, promoting cell regeneration and developing novel medicines. The overarching aim of this research theme is to accelerate the availability and range of innovative cellular and molecular therapies which meet many unmet needs in ophthalmology and in the human body. ...
Technological advances have increased tremendously our understanding of molecular characteristics and genetic drivers for a variety of brain tumors. Although targeted therapies have had a considerable impact on patients outcomes, GBM remains an exception. the identification of targetable driven mutations in GBM has opened new potential treatment options for affected patients. On the basis of these findings, the efficacy of new targeted agents is currently being investigated in clinical trials (Ippen et al, 2018).
Information about on-going clinical trial. The primary objective of the TRAFFIC clinical research studies is to find out if the investigational medicine being studied is effective ...
SummaryBioCardia Inc (BioCardia) is a clinical-stage regenerative medicine company that develops novel therapeutics for cardiovascular diseases.The company develops ...
한국 최고의 가격 Integrative Therapeutics, Inc. 프로 - 포르테 90 소프트 젤 부터 eVitamins.com. 알다 Pros-Forte 리뷰, 부작용, 쿠폰 및 eVitamins에서 더. 한국에 빠르고 신뢰할 수있는 운송. Pros-Forte 다른 제품으로 Integrative Therapeutics, Inc. 당신의 건강 요구에.
Matt Campbell MD Assistant Professor GU Medical Oncology discusses The Argument for Front Line TKI based treatment for non-clear cell RCC at the 18th International Kidney Cancer Symposium 2019, Miami, FL._________Presentation here: https://www.oncologytube.com/video/the-argument-for-front-line-tki-based-treatment-for-non-clear-cell-rccOncologyTube.com is a video sharing platform for cancer physicians.
Lab tests can help you improve your future health. Knowing the predictive biomarkers can guide your lifestyle. Predictive biomarkers are tests that ca...
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: MOLECULAR TARGETS FOR CANCER DRUG DISCOVERY: SBIR/STTR PA-03-021. NCI
Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, ...
Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, ...
These are past and ongoing clinical trials for the last 5 years that patients have been offered at the Institute.... No relevant items found. ...
Colanesi, S., Taylor, K. L., Temperley, N. D., Lundegaard, P. R., Liu, D., North, T. E., Ishizaki, H., Kelsh, R. N. and Patton, E. E., 2012. Small molecule screening identifies targetable zebrafish pigmentation pathways. Pigment Cell & Melanoma Research ...
Our aim is to make significant contributions to understanding the fundamental processes that underlie the immune response to cancer and to translate this into therapeutic opportunities with our NHS partners.
|strong|The Power of Predictive|/strong||a href=http://www.perque.com/Biomarkers_IP_Email/||img class= wp-image-4482 alignleft title=BiomarkersAd ...
Went to Cambridge today for a check-up. As I came out of the lift I bumped into Raven (Robin) - what a small world. I have now met four posters on this site - Raven, Muu, Loriyas and Jaded. Can ...
Metanx - To deny this fact is to deny that any real progress is being made in therapeutics, and this no one of us would be willing to do.
The indicators of liver disease in cats can be a bit ambiguous because they are similar to symptoms of many other diseases and illnesses. Learn about the symptoms of liver disease in cats here.. ...
The challenge in molecular-targeted therapeutics is to identify those signal transduction pathways on which cancer cells have become dependent for their growth and survival. By interrupting these pathways, oncologists hope to arrest tumor cell growth or induce apoptosis more effectively than can be accomplished using cytotoxic chemotherapy and radiation, which impede the growth of cancer cells via nonspecific DNA damage. An emerging theme in cancer therapeutics is that compounds that block specific signaling pathways will be maximally effective against tumors in which the targeted pathway is pathologically hyperactive. For that reason, it is important to test new therapeutic agents in experimental systems that allow the investigator to control which oncogenic signaling pathways are activated.. Models of human medulloblastoma using genetically engineered mice have shown that aberrant activation of the developmentally important Hedgehog signaling pathway in cerebellar neuron precursor cells could ...
Melior Discovery announced two publications describing its lead repositioning candidate, MLR-1023. Both publications will appear in the Journal of Ph
Breaking News in Urologic Oncology:Revised Recommendations for PSA TestingFirst Clinical Trial of New Targeted Molecular Therapy in U.S. Takes Aim at...
Information about on-going clinical trial. The primary objective of the TRAFFIC clinical research studies is to find out if the investigational medicine being studied is effective ...
Project Leaders Prof. Johanna Myllyharju, Ph.D., Scientific Director of Biocenter Oulu Prof. Peppi Karppinen (née) Koivunen, M.D., Ph.D.
Just a month shy of its first birthday, Blend Therapeutics of Watertown, MA, says it has secured $16 million in Series B financing. It plans to use the mon
Calistoga Pharmaceuticals Presents Interim Clinical Efficacy Results from Ongoing Clinical Trial of CAL-101 at the International Workshop on Chronic Lymphocytic Leukemia Treatment with CAL-101
This retrospective study evaluated the effect of Nivolumab in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated in a national early
Among the 518 kinases identified in the human genome are many exciting targets for cancer drug discovery (22). Molecular alterations in numerous kinases have been documented to drive malignant proliferation either via overexpression or activation, the latter secondary to an acquired mutation. Where dependence on a kinase is essential to the phenotype of a tumor, the term oncogene addiction has been coined. It is interesting that where such oncogene addiction is observed, the kinase inhibitors can have dramatic effects, whereas a lesser effect is observed on cells with mere overexpression of the target. An example of this is the activity of gefitinib or erlotinib in lung cancers with or without mutations in epidermal growth factor receptor (23). Can this be considered cytotoxicity on the one hand but cytostasis on the other? On examination of these agents, it becomes clear that the outcome, cytostasis or cytotoxicity, may depend less on the agent and more on the cellular context, especially the ...
Upper GI cancer - Comprehensive molecular evaluation in gastric adenocarcinoma (GC) have revealed four molecular subtypes (TCGA Nature 2014) providing evidence for a number of targetable genetic lesions. Experiences from HER2 testing within the Trastuzumab for Gastric Cancer (ToGA) trial will be presented as one of the first predictive biomarkers in GC. The current status of biomarkers under investigation such as PTEN for AKT/PI3K directed therapies and PD-1/ PD-L1 for immune therapies or markers without proven significance so far (EGFR, VEGF, cMET) will be summarized. Finally, recent developments using multiplex approaches will be addressed ...
The Cancer Therapeutics research program develops cancer drugs to kill cancer cells with few side effects and develops methods to diagnose & find cancer.
Researchers from the Lewis Katz School of Medicine at Temple University and the University of Pittsburgh show that HIV-1 infections can be eliminated from the genomes of living animals. Findings from the study have been published in the journal Molecular Therapy. Genetic Engineering and Biotechnolog...
Seattle Genetics has agreed to pay $250 million up front for global rights to an Immunomedics cancer drug that it says complements the companys pipeline o
Researchers have developed a blood test that might allow doctors to know quickly whether a cancer drug is working. The technique is in the early stages of testi